Breaking News Instant updates and real-time market news.

PTC

PTC

$102.06

1.24 (1.23%)

16:01
04/24/19
04/24
16:01
04/24/19
16:01

PTC names Kristian Talvitie CFO

PTC announced the appointment of Kristian Talvitie as Executive Vice President and Chief Financial Officer, effective May 15, 2019. Talvitie has a broad business background with more than 25 years of finance and sales and marketing experience, including having previously worked at PTC from 2008 to 2016. "Kristian is well-known and highly respected across PTC's management, board of directors, and investor communities," said Jim Heppelmann, president and CEO, PTC. "Kristian joined PTC in 2008 and quickly reshaped our Investor Relations efforts into the award-winning program we have today. Then, as corporate vice president of finance, he led our annual and long-range financial planning efforts during the key time when PTC margins expanded dramatically and growth accelerated as we entered the IoT market."

  • 24

    Apr

PTC PTC
$102.06

1.24 (1.23%)

02/25/19
FBCO
02/25/19
NO CHANGE
Target $47
FBCO
Neutral
Roche may spark another bull run for gene therapy names, says Credit Suisse
Credit Suisse analyst Martin Auster notes that the Wall Street Journal recently reported that Roche (RHHBY) is nearing a deal with Spark Therapeutics (ONCE) for $5B. The analyst believes the transaction value implies the re-emergence of Spark's hemophilia A gene therapy program with a competitive profile and substantial value assigned to additional pipeline programs, such as SPK-3006 for Pompe, and the technology platform. Spark's acquisition would further strengthen the company's position in the hemophilia space, he contends. Further, Auster argues that the deal may increase M&A interest among other gene therapy names in his coverage universe, which include BioMarin (BMRN), Sarepta (SRPT), Ultragenyx (RARE), PTC (PTC) and Solid Biosciences (SLDB). He sees particularly strong read-through to Sarepta. The analyst reiterates a Neutral rating and a $47 price target on Spark's shares.
04/10/19
KEYB
04/10/19
INITIATION
Target $111
KEYB
Overweight
PTC resumed with an Overweight at KeyBanc
KeyBanc analyst Jason Celino resumed coverage of PTC (PTC) with an Overweight rating and a $111 price target. The analyst believes the company has several upside drivers to watch, and continues to benefit from model transition tailwinds. His resellers checks add confidence that Rockwell (ROK) and Ansys (ANSS) partnerships present catalysts for IoT growth and the core business, which could be beginning to ramp.
04/11/19
MZHO
04/11/19
INITIATION
Target $120
MZHO
Buy
PTC initiated with a Buy at Mizuho
Mizuho analyst Matthew Boome initiated PTC with a Buy and $120 price target.
04/11/19
04/11/19
INITIATION
Target $120

Buy
PTC initiated with a Buy at Mizuho
As previously reported, Mizuho analyst Matthew Broome initiated PTC with a Buy rating and a price target of $120. The analyst sees the company's ThingWorx Industrial Internet of Things platform accelerating through new partnerships, and the value of its Vuforia augmented reality offering also "becoming increasingly clear." Broome adds that PTC has "re-energized its legacy Creo computer-aided design business" and anticipates its subscription-based revenue model transition to be highlighted in the coming years.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.